Cerebrolysin Peptide Fragments
| Category | Compounds |
|---|---|
| Also known as | Cerebrolysin Active Fragments, N-PEP-12 |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | neurotrophicstrokeneurodegenerationpeptide-mixtureresearch |
Overview
Cerebrolysin is a porcine brain-derived peptide preparation used clinically in several countries for stroke, dementia, and traumatic brain injury research. The product itself is a complex mixture of low-molecular-weight peptides and free amino acids produced by controlled enzymatic breakdown of brain tissue. Research interest in identifying the specific bioactive "fragments" within Cerebrolysin has grown as investigators aim to reproduce its neurotrophic activity with defined components.
Published characterization has identified sequences with homology to neurotrophic factor active regions, as well as fragments with dipeptidyl peptidase-IV inhibitory activity and antioxidant properties. Related commercial preparations (such as N-PEP-12) are marketed as concentrated fragment fractions derived from similar source material.
Cerebrolysin fragments are typically discussed in research alongside other neurotrophic compounds: P21 peptide, FGL, Semax, Selank, and Dihexa. They are also of interest in stroke and Alzheimer's research.
Structure / Chemistry
Cerebrolysin and its fragment preparations consist predominantly of peptides below 10 kDa along with free amino acids. Individual characterized peptides include short sequences with similarities to BDNF, GDNF, and CNTF active domains. The exact composition varies by manufacturing batch, which is a notable consideration for reproducibility in research.
Mechanism of Action
Proposed mechanisms include engagement of neurotrophin-like signaling pathways (TrkB, p75NTR), modulation of glutamate excitotoxicity, reduction of tau hyperphosphorylation, suppression of neuroinflammatory cytokines, and promotion of adult neurogenesis. Different fragments within the mixture likely contribute to different facets of the overall pharmacology.
Research Summary
| Area | Finding | Reference |
|---|---|---|
| Stroke | Functional recovery improvement in ischemic stroke | Bornstein et al., CNS Neurol Disord 2018 |
| Alzheimer's | Cognitive benefits in mild-moderate AD trials | Alvarez et al., J Alzheimers Dis 2011 |
| TBI | Neurological outcomes after traumatic brain injury | Poon et al., J Head Trauma Rehabil 2020 |
| Neurogenesis | Hippocampal neurogenesis in rodent models | Rockenstein et al., Brain Res 2003 |
| Fragment biology | Identification of neurotrophic-homologous peptides | Hartbauer et al., J Neural Transm 2001 |
Pharmacokinetics
Cerebrolysin is administered by intramuscular or intravenous routes in clinical settings. Individual fragment pharmacokinetics are difficult to define because of the mixture composition. Typical research courses involve daily dosing over several weeks. Specific doses are historical clinical parameters, not guidance.
Common Discussion Topics
- Reproducibility challenges of mixture-based biologics.
- Identification of the most active fragments.
- Comparison with defined peptides like FGL and P21 peptide.
- Regulatory status differences by country.
- Concentrated fragment preparations (N-PEP-12 and related).
Related Compounds
Sourcing research-grade compounds
Obtaining high-purity, research-grade Cerebrolysin Peptide Fragments requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing Cerebrolysin Peptide Fragments. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Cerebrolysin— A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, approved in over 40 countries for stroke, traumatic brain injury, and dementia, though not FDA-approved in the United States.
- Dihexa— A hexapeptide analog of angiotensin IV reported to be up to seven times more potent than BDNF at promoting hepatocyte growth factor signaling, studied primarily for cognitive enhancement and synaptogenesis in animal models.
- FGL— FGL is a short peptide mimetic of NCAM's FGFR-binding site, studied for neurotrophic, cognitive, and neuroprotective activity.
- P21 Peptide— P21 is a CNTF-derived tetrapeptide designed to mimic the active region of ciliary neurotrophic factor, studied for neurogenesis and Alzheimer's disease models.
- Semax— A synthetic heptapeptide analog of ACTH(4-10) developed in Russia as a nootropic and neuroprotective agent, studied for cognitive enhancement, stroke recovery, and BDNF modulation.